Podcasts about DFS

Adam Levitan and Evan Silva react to the biggest and most impactful Free Agency signings so far of the NFL's legal tampering period, analysing the fantasy impact and real-world fallout for each deal.Links mentioned in the episode:ETR's 2026 NFL Free Agency TrackerEstablish The Run GolfEstablish The Run College Basketball BallTimestamps:0:00 - Introduction2:05 - #1 Chiefs Sign RB Kenneth Walker (3yrs, $45m)6:56 - #2 Colts Re-Sign WR Alec Pierce (4yrs, $116m)9:59 - #3 Colts Trade WR Michael Pittman to Steelers12:01 - #4 Steelers Sign RB Rico Dowdle (2yrs, $12.25m)14:21 - #5 49ers Sign WR Mike Evans (3yrs, $60m)19:06 - #6 Saints Sign RB Travis Etienne (4yrs, $52m)24:29 - #7 Patriots Sign WR Romeo Doubs (4yrs, $70m)28:31 - #8 Bucs Sign RB Kenny Gainwell (2yrs, $14m)31:05 - #9 Dolphins Sign QB Malik Willis (3yrs, $67.5m)35:16 - #10 Broncos Re-Sign RB J.K. Dobbins (2yrs, $20m)38:54 - #11 Bears Trade WR DJ Moore to Bills43:19 - #12 Titans Sign WR Wan'Dale Robinson (4yrs, $70m)45:42 - #13 Giants Sign TE Isaiah Likely (3yrs, $40m)47:48 - #14 Cardinals Sign TB Tyler Allgeier (2yrs, $12.25m) 50:41 - #15 Seahawks Sign WR Rashid Shaheed (3yrs, $51m)52:54 - #16 Lions Sign RB Isiah Pacheco55:13 - #17 Chiefs Re-Sign Te Travis Kelce (1yr, $15m)56:39 - #18 Falcons Sign Tua Tagovailoa (1yr, $1.3m)58:10 - #19 Chargers Sign TE Charlie Kolar (3yrs, $24m)59:36 - #20 Raiders Sign C Tyler Linderbaum (3yrs, $81m)1:01:08 - #21 Raiders Trade QB Geno Smith to JetsWant ETR on your team this season? Our 2026 NFL Best Ball product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at ⁠https://establishtherun.com/subscribe/⁠DraftKings: Your Home for Early Bird Best Ball DraftKings Early Bird Best Ball keeps the NFL action going all year long. You draft once, and you're set — no waiver wires, no lineup changes, no weekly grind. DraftKings automatically plays your best lineup every week. DraftKings is your home for Early Bird Best Ball, with $1 million in prizes on the line to make it even better.⁠Sign Up Now⁠! ⁠https://dkng.co/ETRBestBall⁠Gambling Problem? Call 1-800-GAMBLER. New York: call 877-8-HOPENY or text HOPENY. Connecticut: call 888-789-7777 or visit CCPG.org. 18+ in most states. Restrictions apply. Terms: draftkings.com. Sponsored by DraftKings.FREE NEWSLETTER: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: ⁠https://establishtherun.kit.com/email ⁠DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: ⁠https://thesolver.com/?ref=etr⁠SPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: ⁠https://establishtherun.com/offers/⁠FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: ⁠https://linktr.ee/establishtherun⁠

Fantasy managers bring their toughest questions and Dr. A delivers clear, actionable answers. From trade dilemmas and waiver wire pickups to rest-of-season outlooks, this episode is packed with real-time advice to help you gain an edge in your fantasy basketball league. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down Bam Adebayo's massive performance and highlight Dr. A's “My Guys” from Tuesday night. They also dive into the top Bruski 150 performers and discuss the key teams, players, and matchups fantasy managers should be watching heading into Wednesday's games. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down the top waiver wire adds from Tuesday's NBA action and identify players trending toward the drop zone. They also highlight the best streaming options for Wednesday night to help fantasy managers maximize games and gain an edge in their matchups. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Aaron Bruski break down the latest fantasy basketball news and injury updates across the league. They highlight Dr. A's “My Guys” from the night, analyze the top performers from the Bruski 150, and discuss the teams and matchups fantasy managers should watch heading into tonight's games. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A recap Monday's NBA action, highlighting the must-add waiver wire players and key names landing in the drop zone. They also break down the best streaming options for Tuesday to help fantasy managers gain an edge in their matchups. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down their Bruski 150 players and “My Guys” from the weekend, highlighting the standout fantasy performances that matter most. They also dive into the latest league news, injury updates, and the key teams and players to watch heading into tonight's games. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Aaron Bruski break down the must-add waiver wire players and key drop candidates coming out of the weekend. They also highlight the best streaming options for Monday night to help fantasy managers maximize games and gain an edge in their matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send a textWELCOME DNA STRAND CREW TO THE NEWESET EPISODE OF THE DYNASTY DNA CULTURE SHOCK ON THE DYNASTY DNA PODCASTING NETWORK!! This show features the Host of The Dynasty DNA Podcast TJ Blake, Dynasty DNA Team and the one the only Co Host of the Dynasty DNA Deep Dive Bob Helfert (AKA Big Culture Bob) In this show Bob will be breaking down things that he feels are the most important things to talk about following each week of the NFL offseason not only from an NFL perspective but also from a Dynasty Fantasy Football perspective and of course Bob will also give us some of his famous rants we all love fresh off of each and every week!  In this episode the guy's talk the top 5 Devy WR's & TE's currently in college! We talk about things like is Jeremiah Smith the number 1 Dynasty WR once the 2026 draft ends? We also discuss will the transfer to Indiana elevate Nick Marsh? Lastly, do we like Cam Coleman in Texas? It's a great episode tune in with us every week have a few laughs, and let's get you on your way to dynasty championship in 2026 it all begins in the dynasty offseason!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNABob Helfert Bob Helfert (@BigefatBob) / X

Send a textWELCOME TO THE NEWEST EPISODE OF THE FROM WHISTLE TO WHISTLE PODCAST ON THE DYNASTY DNA PODCASTING NETWORK!! This show will feature the Host of The Dynasty DNA Podcasting Network TJ Blake, Dynasty DNA Team Member and Co-Founder Ty Blake, Dynasty DNA team member and Four Corners Radio Founder Mike Shanoudi, And Dynasty DNA team member Justin Tessier! Join us for this fun and factual dynasty show every week where the guys will be rewarded and deducted points based off their arguments on certain dynasty fantasy football questions! The one who ends up with the most points at the end of every episode will be declared the winner! In this episode the guy's talk about things such as how interested are we in Bills DJ Moore as contenders? We also discuss is it ok to gamble a late 2026 1st for Kyler Murray? Lastly, how much can David Montgomery help the Texans offense ? It's a great episode so tune in with us, have a few laughs, and let's get you on your way to dynasty championship in 2026!!!! DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNATy Blake https://mobile.twitter.com/DynastyDnaTyMichael Shanoudi (1) Michael “angry all the time” Shanoudi (@Shanu471) / XJustin Tessier (1) Justin Tessier (@Tessierja91) / X

Dr. A and Tim Woodson break down the top fantasy basketball adds, players trending toward the drop zone, and the best streaming options for the weekend. Get the insights you need to maximize games played and gain an edge in your matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Tim Woodson break down the latest fantasy basketball news, including key injury updates and league developments, before diving into Dr. A's “My Guys” & Tim Woodson Players from Thursday night. The duo highlights the players that stood out, what it means for fantasy managers, and what to watch heading into the weekend. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send a textWELCOME TO THE NEWEST EPISODE OF THE DYNASTY DNA DEEP DIVE PODCAST ON THE DYNASTY DNA PODCASTING NETWORK!! This show features the Host of The Dynasty DNA Podcast TJ Blake, Dynasty DNA Team Member Bob Helfert (AKA Big Bob) and Dynasty DNA team member Noah Hutchinson (AKA SLIM)! In this episode the guys talk would we take a random 2027 1st today or a veteran player!  We discuss things such as who do we have more confidence in longer term Brian Thomas Jr or Rome Odunze? Lastly, would it be crazy to consider potentially re rolling on Emeka Egbuka? It's a great episode so tune in with us, have a few laughs, and let's kick off the offseason right and get you on your way to dynasty championship in 2026!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNABob Helfert Bob Helfert (@BigefatBob) / X

Jason and Pete break down the best DraftKings DFS strategy for UFC 326, including the top fighters to target, value plays, and lineup building strategy to help you win GPP tournaments and cash games. We analyze the entire UFC 326 fight card, looking at: • Best DraftKings DFS picks • Top value fighters for UFC DFS • Fighters to fade • GPP vs Cash lineup strategy • Optimal lineup construction Whether you're playing large-field GPPs or cash games, this breakdown will help you identify the best DFS opportunities for UFC 326. If you enjoy UFC DFS content, DraftKings strategy, and fight breakdowns, make sure to like the video and subscribe for weekly UFC DFS content. Join the Fight HQ Discord https://discord.gg/7Jm7XtT5UD Pete The Heat Patreon https://bit.ly/4iKfJib Fight HQ DraftKings Contest https://www.draftkings.com/draft/contest/188573094 Time Marks 0:00 Intro 1:58 UFC Mexico Recap 4:59 UFC 326 DFS Game Theory 10:56 Max Holloway vs. Charles Oliveira 21:19 Caio Borralho vs. Reiner de Ridder 28:26 Rob Font vs. Raul Rosas Jr. 35:45 Drew Dober vs. Michael Johnson 41:24 Gregory Rodrigues vs. Brunno Ferreira 44:36 Cody Garbrandt vs. Xiao Long 50:04 Donte Johnson vs. Cody Brundage 1:03:53 Ricky Turcios vs. Alberto Montes 1:09:20 Cody Durden vs Nyamjargal Tumendemberel 1:15:13 Sumedaerji vs. Jesus Aguilar 1:17:51 Rafael Tobias vs. Diyar Nurgozhay 1:20:29 Luke Fernandez vs. Rodolfo Bellato 1:27:23 Fight Picks and Listener Questions Subscribe to the Fight HQ Podcast on Apple Podcasts, Spotify, iHeart, or YouTube. The post UFC 326 DraftKings DFS Strategy | Best Picks & Value Fighters appeared first on Radio Influence.

Aaron Bruski and Dr. A break down the upcoming fantasy basketball week (March 9–15), highlighting teams with the best schedules, key back-to-backs, low-volume game days, and the top players to stream. Use schedule advantage to maximize games played and gain an edge in your matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Aaron Bruski recap Wednesday night's fantasy basketball action: spotlighting Doc's “My Guys,” reviewing the top performers from the Bruski 150, and highlighting key players and games to watch heading into Thursday. Essential advice for roster decisions and waiver wire moves. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Aaron Bruski break down Wednesday's top waiver wire adds, debate key drop candidates, and highlight the best streamers to target for Thursday's games. Clear, actionable fantasy advice to help you stay ahead of the competition. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

THIS is March! On this episode, we break down the games from the MAIN Slate for Thursday March 5, 2026 CBB DFS on DraftKings and FanDuel. We go game-by-game to find the top plays, fades, and values on the board to consider when building your lineups!Use code MCONNOLLY88 on UnderDog to get your first deposit matched!https://t.co/FXNtrz6ZBpLink to Patreon: https://t.co/oKODToDCdOFor all of the best offers and promo codes for DFS sites, Player Props sites, and Sportsbooks, use my site at https://signupexpert.com/mikespicks Link to the Fantasy Corner Discord: https://discord.gg/bUCB6aqQed

Send a textThe Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson | Proudly Produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. We explore practical wins and bold ideas across supportive care, colorectal cancer prevention, immunotherapy timing, digital triage and equity. From halving hot flushes with an NK1/NK3 blocker to biomarker-guided aspirin in colon cancer, we weigh value, risk and what truly improves lives.• Elinzanetant cutting severe hot flushes and improving treatment adherence• Current non-hormonal options and gaps in symptom control• Biomarker-selected aspirin reducing recurrences in colorectal cancer• Limits of DFS, toxicity trade-offs and subgroup signals• Rising early-onset colorectal cancer and system planning needs• Possible environmental and microbiome drivers under study• ASCO geriatric assessment guidance and G8 screening in clinics• PD-1 with short-course radiotherapy boosting rectal pCR rates• Large language models for safe, efficient symptom triage• Rare cancers report on access, cost, and rural inequities• Telehealth standards to link expertise closer to home• Healthy workplace culture to retain a resilient oncology workforceJoin the Oncology Network, registration is free, and leave us a voice note on the OJC page at oncologynetwork.com.au. Physicians, don't forget you can claim CME points for listening to the show!Thanks for listening

Adam Levitan and Evan Silva return to assess all the news from the NFL Combine, including trades, breakout performers and key expected releases that are set to shake the fantasy football landscape.Timestamps:0:00 - Introduction1:31 - 1) Detroit Trades RB David Montgomery to Houston6:27 - 2) Is Jahmyr Gibbs The Automatic 1.01 For 2026 Fantasy Drafts?9:23 - 3) Cowboys Re-Sign RB Javonte Williams12:04 - 4) Cowboys Place Franchise Tag on WR George Pickens13:52 - 5) Falcons Place Franchise Tag on TE Kyle Pitts16:44 - 6) Jets Place Franchise Tag on RB Breece Hall19:28 - 7) Colts Place Transition Tag on Daniel Jones22:25 - 8) Colts Give QB Anthony Richardson Permission To Seek Trade24:21 - 9) Rumors Suggest Giants In Market For RB26:43 - 10) Rumours Surrounding AJ Brown, Dallas Goedert & David Njoku30:51 - 11) Vikings Expected To Release RB Aaron Jones32:27 - 12) Cardinals Expected To Release QB Kyler Murray36:20 - 13) Notre Dame RB Jeremiah Love Smashes The Combine40:54 - 14) Ohio State WR Carnell Tate Sinks Stock, Only Running 4.5343:41 - 15) USC WR Makai Lemon Reportedly Bombs Interviews46:01 - 16) Arkansas RB Mike Washington Posts 4.33 Time, Rockets Up Big Boards48:37 - 17) Oregon TE Kenyon Sadiq & Vanderbilt TE Eli Stowers Blow Up The Combine50:27 - 18) Broncos OC Davis Webb Expected To Call Plays In Denver51:49 - 19) Commanders OC David Blough Wants To Get WR Terry McLaurin "10 Targets A Game"54:17 - 20) The NFL Combine Performances Are Skewed, How Do You Fix It?56:09 - 21) Bears C Drew Dalman Announces Unexpected RetirementWant ETR on your team this season? Our 2026 NFL Best Ball product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://establishtherun.com/subscribe/DraftKings: Your Home for Early Bird Best Ball DraftKings Early Bird Best Ball keeps the NFL action going all year long. You draft once, and you're set — no waiver wires, no lineup changes, no weekly grind. DraftKings automatically plays your best lineup every week. DraftKings is your home for Early Bird Best Ball, with $1 million in prizes on the line to make it even better.Sign Up Now! https://dkng.co/ETRBestBallGambling Problem? Call 1-800-GAMBLER. New York: call 877-8-HOPENY or text HOPENY. Connecticut: call 888-789-7777 or visit CCPG.org. 18+ in most states. Restrictions apply. Terms: draftkings.com. Sponsored by DraftKings.FREE NEWSLETTER: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://establishtherun.kit.com/email DFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: https://thesolver.com/?ref=etrSPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: https://establishtherun.com/offers/FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: https://linktr.ee/establishtherun

Dr. A highlights his “My Guys” from Tuesday night, Aaron Bruski breaks down key performances from the Bruski 150, and the crew previews the most important fantasy storylines heading into Wednesday's slate. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A answers your toughest fantasy basketball questions in this live Q&A special. From trade decisions and waiver pickups to rest-of-season strategy, get actionable insight to help you stay ahead of your league. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. A and Aaron Bruski break down Tuesday night's top waiver wire adds, debate key Drop Zone decisions, and highlight the best fantasy streamers to help you gain an edge on Wednesday. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Etoft21sports Show is back with another loaded episode! This week, host Erik welcomes David (aka @bettordp21 on social media) to break down the college basketball weekend that was and dive into their best bets for Wednesday's college basketball slate. The guys will analyze key matchups, betting angles, and where they see value on the board. Plus, Gino from Daily Racing Form (DRF.com) joins the show with his Horse Racing Bet of the Day. Last week? The show went 4-2 on its bets — and Gino's horse racing play cashed as well. Let's keep it rolling.

THIS is March! On this episode, we break down the games from the MAIN Slate for Wednesday March 4, 2026 CBB DFS on DraftKings and FanDuel. We go game-by-game to find the top plays, fades, and values on the board to consider when building your lineups!Use code MCONNOLLY88 on UnderDog to get your first deposit matched!https://t.co/FXNtrz6ZBpLink to Patreon: https://t.co/oKODToDCdOFor all of the best offers and promo codes for DFS sites, Player Props sites, and Sportsbooks, use my site at https://signupexpert.com/mikespicks Link to the Fantasy Corner Discord: https://discord.gg/bUCB6aqQed

The guys break down their Arnold Palmer Invitational PGA DFS picks and favorite DraftKings plays for 2026! With the field set to compete at the famed Bay Hill, we analyze the top golf betting strategies and PGA Tour DFS ownership trends you need to know.In this video, Keith Flemming & Scott Porter cover their Top 5 plays, sleepers, and fades to help you cash your lineups on DraftKings and FanDuel. Whether you are looking for DFS golf advice or the best sports betting odds, this preview gives you the edge for this week's event.Timestamps:0:00 - Arnold Palmer Invitational PGA DFS Picks & Best Bets1:43 - Venue Preview (Bay Hill)14:26 - DFS Plays39:31 - Bets to Win59:44 - Jon RahmAlso, don't miss Keith's full tournament preview, hand-picked stats for research, and his DFS and Betting Cheat Sheets for this week's Arnold Palmer Invitational. Check them out!Best Bets: https://fantasysixpack.net/pga-bets-t...DFS Cheat Sheet: https://fantasysixpack.net/pga-dfs-ch...DFS Stats: https://fantasysixpack.net/this-weeks...Stay connected with Keith and Scott on Twitter and BlueSky for the latest updates and insights:Keith Flemming:Twitter: @KeithFlemmingBlueSky: keithflemming.bsky.socialScott: @sportergolf

In this episode of Bring the Pain, Dan and I are back with a different kind of show since I'm having surgery on Thursday. Since a lot of the odds aren't out yet, we'll only have the money lines and Draft Kings DFS to give you. That being said, we'll also be reviewing UFC Mexico so that you get the Hard Hits Review and the Fight Club rolled into one. We couldn't leave any of you hanging going into a huge event like this, and I should be somewhat coherent by Saturday. That means you'll have to get to the Subs-only Discord at Dr. Roto, for all of my bets and parlays, if I'm aware by then. Have a great day, everyone, and may the fights be with you. Thank you for the support and contributions all of you make for my podcasts and articles each week. Y'all the real #Painbringers! Follow me at.... *Facebookhttps://www.facebook.com/Bring... *Twitterhttps://twitter.com/HeatOverid... *Spreaker Podcastshttps://spreaker.page.link/VS5... *Dr Roto Sports Websitehttps://drroto.com/author/robe... *You Tubehttps://youtube.com/@Heat00veride05?si=cVb49FjQD-Y6fKjT *Apple Podcastshttps://podcasts.apple.com/us/... *Spotify Podcastshttps://open.spotify.com/show/... *Podchaser Podcastshttps://www.podchaser.com/podc... *Iheart Podcastshttps://www.iheart.com/podcast... #drroto​ #bringthepain​ #fightclubofpain​ #hardhitsreview​ #review​ #podcast​ #ufcodcast​ #podcast​ #spreakerpodcast​ #spreaker​ #fighttheory​ #ufcsheriffs​ #ufc​ #ufc326​ #hollowayvsoliveira​ #betting​ #sportsbetting​ #dfs​ #dfslineups​ #propbets​ #specialshow​ #soupcanoftheweek​ #parlayofpain​ #season8finale​ #dubbyenergy​ #twitch​ #youtube​Become a supporter of this podcast: https://www.spreaker.com/podcast/bring-the-pain--3659369/support.

Dr. A shares his ‘My Guys,' Aaron Bruski breaks down the top 150 players, and we highlight the key matchups and streamers to watch, all to help you dominate your fantasy basketball week! Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski breaks down all 30 NBA teams, identifying the key storylines and player values that will shape the rest of your fantasy basketball season. Find out who's rising, who's risky, and what truly matters going forward. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down the top waiver wire adds after Monday's games, debate which performances are sustainable, and identify players sliding into the Drop Zone. Then they preview the best streamers for Tuesday's slate in both standard and deep leagues so you can stay ahead of your matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Short Kings Pritchard and Reed win the night

Danger and Adam run through the field at this week's #PGA #DFS main slate on #Draftkings powered by #DrRoto

The PGA Tour is BACK! On this episode, we break down the 2026 Arnold Palmer Invitational. Everything you need to know, in 30 minutes or less. We discuss the uniqueness of this event and the host course, Bay Hill, we take a look at the key stats for who might perform well this week before diving into the top DFS Plays, Best Bets, and make our One and Done selection!Link to the Editable Spreadsheet: https://docs.google.com/spreadsheets/d/1bGPiyXt4D06N6XEdoPz2AcbOZuhsFXGJpu0oTa7bQaM/edit?usp=sharing Link to sign up for Splash Sports to play other One and Done contests: https://app.splashsports.com/sign-up?referralCode=YL9ABQUse code MCONNOLLY88 on UnderDog to get your first deposit matched!https://t.co/FXNtrz6ZBpLink to Patreon: https://t.co/oKODToDCdOFor all of the best offers and promo codes for DFS sites, Player Props sites, and Sportsbooks, use my site at https://signupexpert.com/mikespicks Link to the Fantasy Corner Discord: https://discord.gg/bUCB6aqQed

Aaron Bruski and Dr. A break down the latest injury updates around the NBA, including Steph Curry, Joel Embiid and key fantasy impacts. Then they highlight standout performances from the weekend, review Bruski 150 risers and fallers, and preview the most important games to monitor heading into Monday night. If you're navigating injuries and gearing up for the fantasy playoffs, this episode is a must-listen. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down the biggest waiver wire adds after the weekend, highlight players landing in the Drop Zone, and give you the best streaming targets for Monday's slate. Whether you're protecting a lead or chasing categories, this episode gives you actionable advice to win your matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this news-style episode, Simon and Dan break down Citrini Research’s The 2028 Global Intelligence Crisis—a “note from the future” dated June 30, 2028 that frames the most bullish AI adoption path as a surprisingly bearish outcome for the real economy. They walk through the core feedback loop: companies deploy AI to boost productivity and margins, layoffs rise (especially in white-collar roles), consumer spending weakens, and the cycle reinforces itself—creating what the piece calls “ghost GDP,” where productivity climbs but wages and demand don’t keep up. From there, the duo digs into the sectors Citrini argues get hit first and hardest: SaaS (seat contraction + customers using AI as renewal leverage), the intermediation layer (agents shopping travel, subscriptions, insurance, delivery, and more), and even payment rails as AI agents chase lower-cost settlement via stablecoins. They also connect the dots to private credit and insurance flywheels—where mark-to-model portfolios can look stable until forced selling and capital needs expose stress—and what rising unemployment could mean for housing in once “prime” white-collar markets. Tickers discussed: V, MA, AXP, DFS, PYPL, AMZN, WMT, EXPE, UBER, DASH, SHOP, GOOGL, PLTR, TRI, OWL, APO, BN, KKR, CRM, ADBE, AIG Citrini research report Subscribe to our Our New Youtube Channel! Check out our portfolio by going to Jointci.com Our Website Our New Youtube Channel! Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Fiscal.ai for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

Send a textWELCOME DNA STRAND CREW TO THE NEWESET EPISODE OF THE DYNASTY DNA CULTURE SHOCK ON THE DYNASTY DNA PODCASTING NETWORK!! This show features the Host of The Dynasty DNA Podcast TJ Blake, Dynasty DNA Team and the one the only Co Host of the Dynasty DNA Deep Dive Bob Helfert (AKA Big Culture Bob) In this show Bob will be breaking down things that he feels are the most important things to talk about following each week of the NFL offseason not only from an NFL perspective but also from a Dynasty Fantasy Football perspective and of course Bob will also give us some of his famous rants we all love fresh off of each and every week!  In this episode the guy's talk dynasty fantasy football trade advice for contenders and rebuilders! Don't bite on the low-ball Malik Nabers offers? Lastly, why players like Xaiver Worthy & Anthony Richardson are good throw in's for trades but not good buy lows!  It's a great episode tune in with us every week have a few laughs, and let's get you on your way to dynasty championship in 2026 it all begins in the dynasty offseason!Join The DNA Strand Crew on Discord Free to Join Just Click This Link!!https://discord.gg/rFAyWzn8Join the DNA Strand Crew on Twitterhttps://mobile.twitter.com/DynastyDNA_Subscribe to The Dynasty DNA YouTube Channel(9) Dynasty DNA Fantasy Football Podcast - YouTubeFollow The DNA Guys On TwitterTJ Blake https://twitter.com/TJBlakeDNABob Helfert Bob Helfert (@BigefatBob) / X

THIS is March! On this episode, we break down the games from the MAIN Slate for Monday March 2, 2026 CBB DFS on DraftKings and FanDuel. We go game-by-game to find the top plays, fades, and values on the board to consider when building your lineups!Use code MCONNOLLY88 on UnderDog to get your first deposit matched!https://t.co/FXNtrz6ZBpLink to Patreon: https://t.co/oKODToDCdOFor all of the best offers and promo codes for DFS sites, Player Props sites, and Sportsbooks, use my site at https://signupexpert.com/mikespicks Link to the Fantasy Corner Discord: https://discord.gg/bUCB6aqQed

Aaron Bruski and Dr. A break down everything you need to dominate the week ahead in fantasy basketball. From top streaming targets and favorable schedules to matchup advantages and hidden edges, this episode gives you the roadmap to win your week before it even begins. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down Thursday night's biggest fantasy takeaways, highlighting priority waiver adds, concerning drop-zone performances and potential buy-low opportunities. The guys also dive into weekend schedule strategy, identifying teams with advantageous Friday–Sunday slates and the best streaming targets to help you maximize games played and category impact. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down Thursday night's biggest fantasy takeaways, including injury updates from stars like Jabari Smith Jr., Lauri Markkanen, Trae Young, and Devin Booker. The guys highlight their “My Guys” and the Bruski 150 top performers, while giving actionable insight into who to roster, stash, or stream heading into the weekend. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Lakers fall apart plus the west gets tightened up.

Aaron Bruski and Dr. A sort through a packed Wednesday slate filled with impactful injury news and eye-popping stat lines. The guys react to updates on James Harden, Keegan Murray, Daniel Gafford and others, then highlight standout performances. They also dig into emerging waiver names, shifting rotations, and the key teams to monitor heading into tonight's games. Clear, actionable analysis designed to keep your roster one step ahead. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A break down the biggest fantasy takeaways from Wednesday night's action. From surprise stat lines and emerging waiver targets to concerning performances from established names, the guys sort through what's actionable and what's noise. They also dive into the Drop Zone, identifying potential buy-lows and cut candidates, before closing with the top streamers to help you win Thursday's slate in both standard and deep leagues. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Off the back of a hugely successful 2025 fantasy season, Adam Levitan leads a star-studded ETR lineup of Fantasy experts with Evan Silva, Justin Herzig, John Daigle, Sam Brott and Jack Miller in our first 2026 Fantasy Football Draft.Want ETR on your team this season? Our 2026 NFL Best Ball product has you covered with:Real-Time RankingsResearch & Analysis ArticlesDraft Strategy ContentDraft LivestreamsDiscord CommunityQ&As with ETR TeamSubscribe now at https://establishtherun.com/subscribe/FREE NEWSLETTER: Tired of attention-seeking hot takes? Get the highest-quality fantasy football analysis in your inbox, FREE: https://establishtherun.kit.com/emailDFS OPTIMIZER: Sign up for THE SOLVER for access to the software we think fantasy players need to win: ⁠https://thesolver.com/?ref=etr⁠SPORTSBOOK OFFERS: We've partnered with several major sportsbook outlets to help supply you with the best offers in the industry and ensure you're maximizing your bankroll from the start: ⁠https://establishtherun.com/offers/⁠FOLLOW US: Check out our social media channels for FREE fantasy football & DFS videos, analysis, and more: ⁠https://linktr.ee/establishtherun⁠

Steve Alexander and William Harris analyze Tuesday's biggest fantasy performances, separating sustainable production from short-term noise. The guys highlight priority waiver adds, concerning drop candidates and the strongest streaming options for Wednesday's slate to help you maximize your matchup. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The injury news keeps stacking up, and fantasy managers need to react fast. Dr. A and William Harris break down updates on Jalen Suggs, Jalen Johnson, Anfernee Simons, Shaedon Sharpe and Aaron Gordon, plus what those developments mean for rotations and waiver opportunities. The guys also highlight Tuesday night's biggest fantasy performances, including Tyrese Maxey, Cason Wallace and Neemias Queta, and close with what they're watching heading into tonight's slate. Actionable insight to help you stay ahead of your league. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aaron Bruski and Dr. A analyze the night's biggest stat lines and dig deeper into what's sustainable versus short-term noise. From emerging contributors to shifting rotations and category boosts, this episode focuses on actionable fantasy insight that helps you make sharper roster decisions. Presented by FanDuel Download the SportsEthos App on the APP Store and Google Play! FantasyPass now includes DAILY PROJECTIONS - perfect for DFS and head-to-head leagues. Join the Discussion on DISCORD for real-time advice and community support. Subscribe, Rate, and Review on Apple and Spotify for expert updates and tips! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.